Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Capital Expenditures: 2022-2025

Historic Capital Expenditures for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $58,000.

  • Axsome Therapeutics' Capital Expenditures fell 35.56% to $58,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $439,000, marking a year-over-year increase of 77.73%. This contributed to the annual value of $270,000 for FY2024, which is 53.61% down from last year.
  • Axsome Therapeutics' Capital Expenditures amounted to $58,000 in Q3 2025, which was up 346.15% from $13,000 recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Capital Expenditures high stood at $371,000 for Q3 2023, and its period low was $7,000 during Q4 2023.
  • Moreover, its 3-year median value for Capital Expenditures was $71,000 (2023), whereas its average is $114,636.
  • Over the last 5 years, Axsome Therapeutics' Capital Expenditures had its largest YoY gain of 462.12% in 2023, and its largest YoY loss of 96.13% in 2023.
  • Axsome Therapeutics' Capital Expenditures (Quarterly) stood at $181,000 in 2022, then tumbled by 96.13% to $7,000 in 2023, then soared by 328.57% to $30,000 in 2024, then tumbled by 35.56% to $58,000 in 2025.
  • Its Capital Expenditures stands at $58,000 for Q3 2025, versus $13,000 for Q2 2025 and $338,000 for Q1 2025.